Get the Stockscreener App
2.46
5.13%
0.12
After Hours:
2.50
0.04
+1.63%
In 8 Bio Inc stock is traded at $2.46, with a volume of 257.56K.
It is up +5.13% in the last 24 hours and up +38.20% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$2.34
Open:
$2.32
24h Volume:
257.56K
Relative Volume:
1.00
Market Cap:
$24.01M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-3.28
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
+10.31%
1M Performance:
+38.20%
6M Performance:
+13.89%
1Y Performance:
-70.74%
1-Day Range:
$2.25
$2.59
1-Week Range:
$1.9301
$2.59
52-Week Range:
$1.17
$12.53
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.46 | 22.84M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade - ts2.tech
The economy: Top biopharma trends of 2025 - BioWorld MedTech
Intelligent Bio Solutions Inc Announces New Manufacturing Partnership - TradingView — Track All Markets
Climb Bio, Inc. Files Legal Complaint Over Asset Purchase Agreement - TradingView — Track All Markets
New gut-targeted drug gains key patent in Japan for severe bowel disease - Stock Titan
10 Stocks Lighting Up Market Ahead of Christmas - Insider Monkey
Ginkgo Bioworks (NYSE: DNA) realigns leadership as Shetty refocuses on lab - Stock Titan
ImmunityBio (NASDAQ: IBRX) boosts ATM capacity and ups authorized shares - Stock Titan
Palisade Bio: Gut Prodrug For IBD With Catalysts - Seeking Alpha
What technical signals suggest for GRI Bio Inc. stockEarnings Growth Report & Safe Entry Point Identification - Улправда
Why Cabaletta Bio Inc. stock remains on watchlistsJuly 2025 Institutional & Weekly High Conviction Trade Ideas - Улправда
INmune Bio Signs Sales Agreement With A.G.P./Alliance Global Partners - TradingView — Track All Markets
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical
Why GRI Bio Inc. stock remains on buy listsShare Buyback & Stepwise Trade Signal Implementation - Улправда
How sustainable is TELA Bio Inc. stock dividend payout2025 Pullback Review & Low Risk High Win Rate Picks - Улправда
Korro Bio (KRRO) boosts Jeffrey Cerio salary, severance and RSU grant - Stock Titan
Can Third Harmonic Bio Inc. stock withstand economic slowdownTrade Risk Assessment & Reliable Entry Point Alerts - Улправда
Pre Market Movers: ALGS, PDSB, PCSA Swing Big - RTTNews
Kala Bio (NASDAQ: KALA) details dismissal of Deloitte as auditor - Stock Titan
KALA BIO (Nasdaq: KALA) details Lazar financing shift and 2026 meeting - Stock Titan
BioCardia (NASDAQ: BCDA) moves to PMDA consultation on heart failure therapy - Stock Titan
Owner RA Capital Management LP Buys 314,561 ($754.7K) Of Climb Bio Inc [CLYM] - TradingView — Track All Markets
[8-K] ImmunityBio, Inc. Reports Material Event | IBRX SEC FilingForm 8-K - Stock Titan
BioXcel Therapeutics (NASDAQ: BTAI) wins approval for reverse stock split plan - Stock Titan
GRI Bio (Nasdaq: GRI) details closing of offering, equity over $2.5M post-transaction - Stock Titan
GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewswire
GRI Bio (NASDAQ: GRI) details $6.7M equity deal and runway into Q4 2026 - Stock Titan
GRI Bio (NASDAQ: GRI) prices $8,000,000 offering of 10,666,667 shares at $0.75 - Stock Titan
Inmune Bio Ends Sales Agreement with RBC and BTIG - TipRanks
GRI Bio, Inc. Announces Positive Phase 2a Trial Results for GRI-0621 - TradingView
GRI Bio (NASDAQ: GRI) unveils Phase 2a IPF results showing favorable safety and collagen biomarker shifts - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GRI Bio (NASDAQ: GRI) updates Form S-1 with extensive warrant and contract exhibits - Stock Titan
Chmn Hoffman Buys 45,000 ($193.8K) Of Annovis Bio Inc [ANVS] - TradingView — Track All Markets
GRI Bio Reports Positive Phase 2a Trial Results for IPF Treatment - TradingView
GRI Bio (NASDAQ: GRI) reports Phase 2a IPF topline results for GRI-0621 - Stock Titan
GRI Bio (Nasdaq: GRI) reports positive IPF Phase 2a results and warrant offering - Stock Titan
The 4 billion won investment quietly implemented by Yuhan four years ago returned to a "large jackpo.. - 매일경제
Pres Kalowski Sells 9,072 ($31.4K) Of Q32 Bio Inc [QTTB] - TradingView
CEO Morrison Sells 22,506 ($77.9K) Of Q32 Bio Inc [QTTB] - TradingView
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
KALA BIO (NASDAQ: KALA) prices $10M registered direct sale of 10M shares at $1.00 - Stock Titan
Nuvation Bio (NUVB) Chief Medical Officer reports 150K share sale and option exercise - Stock Titan
Upstream Bio (NASDAQ:UPB) Shares Down 8%Here's What Happened - MarketBeat
INMB SEC FilingsInmune Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Palisade Bio (Nasdaq: PALI) appoints GI trials expert Izanec VP, Clinical Development - Stock Titan
KALA BIO (NASDAQ: KALA) inks $6M securities deal, appoints David Lazar CEO and chair - Stock Titan
What insider trading reveals about GRI Bio Inc. stockWeekly Gains Summary & Long-Term Safe Investment Ideas - moha.gov.vn
Climb Bio, Inc. (CLYM) Stock Price, News, Quote & History - Yahoo! Finance Canada
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):